Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07133308 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
A Phase 3 study of Alopecia Areata, sponsored by Sun Pharmaceutical Industries.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 355
- Enrollment target
- 20
- Study locations
NCT07133308 is a Phase 3 study of Alopecia Areata that is actively recruiting participants, run by Sun Pharmaceutical Industries. The registered enrollment target is 355 participants, below the 1,942-participant average among 26 other Alopecia Areata trials with a reported enrollment target (82% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT07133308, a Phase 3 study of Alopecia Areata, is actively recruiting participants, sponsored by Sun Pharmaceutical Industries.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 355 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study evaluates the safety and effectiveness of deuruxolitinib in adolescents aged 12 to less than 18 years who have 50% or greater scalp hair loss.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Deuruxolitinib
Study Locations (20)
Florida
- D&H Doral Research Center - Doral
- Skin Care Research, Llc - Hollywood - Hollywood
- Ilumina Medical Research Llc - Kissimmee
- All X Ray Diagnostic Services Corp - Miami
- Millennium Medical Research Llc - Miami
- Florida International Medical Research - Miami
- Florida Pharmaceutical Research And Associates, Inc. - Miami
- L&C Professional Medical Research Institute - Miami
- Pediatric Skin Research Llc - Miami
- Valencia Medical & Research Center - Miami
California
- Kern Research Inc. - Bakersfield
- Center For Dermatology Clinical Research Inc. - Fremont
- Dermatology Research Associates - Los Angeles
- Palmtree Clinical Research - Palm Springs
- Paradigm Clinical Research - San Diego - San Diego
Colorado
- Colorado Medical Research Center - Denver
- Paradigm Clinical Research - Wheat Ridge - Wheat Ridge
Alabama
- Total Skin And Beauty Dermatology Center - Birmingham
Arizona
- Avacare - Cct Research - Center For Dermatology And Plastic Surgery - Scottsdale
Arkansas
- Dermatology Trial Associates - Bryant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 355 participants |
| Start Date | 2025-08-05 |
| Est. Completion | 2028-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07133308
The ClinicalTrials.gov registry entry for NCT07133308 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 355 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,942-participant average among 26 other Alopecia Areata trials with a reported enrollment target (82% lower). The listed sponsor is Sun Pharmaceutical Industries, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alopecia Areata appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07133308 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Florida, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT07133308 about?
NCT07133308 is a clinical study titled "Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata". This study evaluates the safety and effectiveness of deuruxolitinib in adolescents aged 12 to less than 18 years who have 50% or greater scalp hair loss.
What is the current status of trial NCT07133308?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 355 participants. The study started on 2025-08-05. Estimated completion is 2028-05.
What conditions does trial NCT07133308 study?
This clinical trial studies the following conditions: Alopecia Areata.
What interventions are being tested in trial NCT07133308?
The interventions under investigation include: Placebo (DRUG), Deuruxolitinib (DRUG).
Who is sponsoring clinical trial NCT07133308?
This trial is sponsored by Sun Pharmaceutical Industries, which has 48 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07133308 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alopecia Areata
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
RECRUITING · Phase 3
-
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
RECRUITING · Phase 3
-
Long-Term PF-06651600 for the Treatment of Alopecia Areata
ACTIVE NOT RECRUITING · Phase 3
-
Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata
RECRUITING · Phase 2
-
A Study of LAD603 in Adults With Alopecia Areata
RECRUITING · Phase 2
-
A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.